Florida Laboratory Analysis, LLC

Florida Laboratory Analysis, LLC was paid $103K by Medicaid between Aug 2018 and Sep 2023, across 51 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 67% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#102 of 225

Median peer was paid$74K

This provider vs. median1.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	237	$0.00
2019	3,190	$0.00
2020	18,937	$52K
2021	30,666	$51K
2022	19,732	$100.00
2023	16,585	$0.00

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	67%	13,040	4,327	$69K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	9,241	3,326	$17K
87481		5.2%	764	454	$5K
80053	Comprehensive metabolic panel	4.0%	4,088	2,885	$4K
83036	Hemoglobin; glycosylated (A1C)	1.6%	2,218	1,631	$2K
80048	Basic metabolic panel (calcium, ionized)	1.6%	755	410	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,844	3,224	$825.40
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,796	1,275	$535.58
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	7,474	2,258	$492.66
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	129	87	$408.09
86769		<1%	75	38	$321.32
84439		<1%	1,249	890	$304.19

39 more codes

80061	Lipid panel	<1%	2,854	$229.78
82607		<1%	1,841	$201.72
84443	Thyroid stimulating hormone (TSH)	<1%	3,015	$187.54
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	13,304	$143.90
82040		<1%	19	$109.73
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,610	$63.38
87581		<1%	124	$59.52
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	758	$51.33
81000		<1%	520	$27.27
82746		<1%	1,154	$26.22
36415	Collection of venous blood by venipuncture	<1%	5,534	$19.32
80165		<1%	119	$16.54
80076		<1%	177	$16.34
87653		0%	764	$0.00
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	0%	2,374	$0.00
87641		0%	603	$0.00
87150		0%	1,384	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	948	$0.00
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	0%	1,695	$0.00
83540		0%	15	$0.00
80306		0%	1,012	$0.00
82140		0%	24	$0.00
84481		0%	463	$0.00
82947		0%	12	$0.00
84466		0%	15	$0.00
84155		0%	19	$0.00
87640		0%	604	$0.00
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	0%	18	$0.00
83735		0%	209	$0.00
82043		0%	184	$0.00
84153		0%	96	$0.00
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	0%	879	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	691	$0.00
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	0%	351	$0.00
87486		0%	130	$0.00
84436		0%	30	$0.00
82945		0%	81	$0.00
84480		0%	29	$0.00
82728		0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGWYNN, SHERRI (BILLING MANAGER)